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Abstract: Photodynamic therapy (PDT) is a clinically approved anti-cancer treatment that 
involves the activation of an otherwise inactive sensitisier drug with light, which in the 
presence of molecular oxygen, generates cytotoxic reactive oxygen species (ROS). As 
oxygen is a key requirement for the generation of ROS in PDT and given the fact that 
hypoxia is a characteristic of most solid cancerous tumours, treating hypoxic tumours using 
PDT can be a challenge. In this manuscript, we have prepared a CaO2 nanoparticle (NP) 
formulation coated with a pH-sensitive polymer to enable the controlled generation of 
molecular oxygen as a function of pH. The polymer coat was designed to protect the 
particles from decomposition while in circulation but enable their activation at lower pH 
values in hypoxic regions of solid tumours. The oxygen generating capability of the polymer 
coated NPs was demonstrated in aqueous solution with minimal oxygen produced at pH 7.4, 
whereas it increased significantly when the pH was reduced to 6.2. The polymer coated 
CaO2 NPs were also observed to significantly increase tumour pO2 levels (p<0.05) in mice 
bearing ectopic human xenograft  MIA PaCa-2 pancreatic tumours with an average increase 
in tumour pO2 of 6.5 mmHg in the period 10-30 min following administration. A statistically 
significant improvement in PDT mediated efficacy (p<0.001) was also observed when the 
particles were administered to mice bearing the same tumours 20 min prior to PDT 
treatment. These results suggest that the polymer coated CaO2 NP formulation offers 
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significant potential as an in situ method for oxygen generation to enhance the efficacy of 
treatments that depend on the presence of oxygen to elicit a cytotoxic effect.  
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1.0 Introduction: Photodynamic therapy (PDT) is a cancer treatment that involves 
irradiating a photoactive drug with light, in the presence of molecular oxygen, to generate 
toxic levels of Reactive Oxygen Species (ROS) ultimately resulting in cell death.[1] By 
carefully controlling light delivery to the target lesion, ROS generation can be localised with 
high precision in three dimensions sparing healthy surrounding tissue. While the targeted 
nature of PDT remains its greatest attraction, the technique is significantly limited by the 
inability of light to penetrate deeply through human tissue.[2] This has restricted PDT to the 
treatment of superficial lesions and hindered its ability to treat larger solid tumours. The 
development of near-infrared (NIR) absorbing sensitisers and the emergence of 
sonodynamic therapy (SDT) promise to overcome this limitation by enabling the activation of 
sensitisers at greater depths in vivo.[3] Combatting hypoxia presents another challenge in 
the treatment of solid tumours using PDT / SDT as oxygen is a key requirement for the 
generation of ROS. This is particularly true for tumours of the pancreas[4] and hypoxia is 
now recognised as an indicator of poor prognosis for many types of cancer.[5,6] Inefficient 
gas and mass transfer resulting from atypical vascularisation together with elevated oxygen 
demand by hyper-proliferating tissues results in hypoxia in most solid tumours. Once a 
hypoxic environment develops in the tumour, cell populations become resistant to many 
conventional cancer chemotherapeutic agents through a variety of adaptive survival 
mechanisms. Similarly, for radiotherapy, oxygen has been shown to play a very significant 
role in enhancing radiation induced damage to nucleic acid in target tissues.[7] One of the 
major challenges associated with the latter has been to provide oxygen to the target tissues 
during therapy. A number of approaches have been employed including, hyperbaric oxygen 
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breathing and breathing pure oxygen or carbogen at atmospheric pressure.[8] Such 
approaches, however, have delivered limited success and there is still a significant un-met 
need in this area. We have recently demonstrated that the selective destruction of oxygen 
loaded microbubbles in the tumour microenvironment using low intensity ultrasound provided 
a temporary boost in tumour oxygen levels that enhanced the sonodynamic therapy (SDT) 
treatment of pancreatic tumours.[9] Inspired by these results, we are also focusing on the 
development of in situ oxygen generating nanoparticles as an alternative method to improve 
tumour oxygenation during PDT. 
 In this manuscript, we describe the preparation and characterisation of calcium 
peroxide (CaO2) nanoparticles that generate molecular oxygen upon decomposition in water. 
The nanoparticles were coated with a pH-responsive methacrylate based co-polymer 
containing a tertiary amine residue that protects the nanoparticle core from water at pH 
values above 7.4. At lower pH values, the tertiary amine unit ionises resulting in dissolution 
of the polymer coat and exposure of the nanoparticle core to the aqueous environment 
resulting in oxygen generation (Scheme 1).   
 
 
 
Scheme 1 Schematic illustration of how the polymer coat (green) protects the nanoparticle 
core (blue) from its aqueous environment at normal pH but at lower pH, the polymer coat 
dissolves, allowing access to the core by water with the resulting generation of oxygen.  
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Tumour tissue interstitial fluid is more acidic (pH = ~6.0) than normal tissue, as hypoxia 
results in the accumulation of acid by inducing the production of energy from glycolysis via 
the Pasteur effect.[10] This difference in pH has been utilised in numerous pH-responsive 
cancer therapeutics and diagnostic probes.[11] Here, the pH-responsive polymer coat will 
limit NP decomposition in the blood and normal tissue while facilitating its decomposition in 
more acidic cancer tissue. The ability of the resulting oxygen generation to improve 
oxygenation in hypoxic environments and enhance the PDT-mediated treatment of BxPC-3 
pancreatic cancer cells in vitro and human xenograft MIA-PaCa-2 pancreatic tumours in vivo 
is demonstrated. 
2.0  Materials and Methods 
2.1 Reagents and equipment: Calcium chloride, PEG 200, 1M ammonia solution, 35% 
hydrogen peroxide, sodium hydroxide, phosphate buffered saline (PBS), luminol, methanol, 
ethanol, hexane, chloroform, Rose Bengal (RB), singlet oxygen sensor green (SOSG), 
anhydrous tetrahydrofuran (THF), 2-(dimethylamino)ethyl methacrylate, methyl 
methacrylate, ethyl acrylate and 1,1'-Azobis(cyclohexanecarbonitrile) (ABCN) were 
purchased from commercial sources at the highest possible grade. BxPC-3 and MIA PaCa 
cells were obtained from the American Type Culture Collection (ATCC) and matrigel from 
BD Biosciences,Erembodegem, Belgium. SCID mice (C.B-17/IcrHanHsd-PrkdcSCID) were 
bred in house. Scanning electron microscopy (SEM) analysis was conducted using an “FEI 
Quanta” scanning electron microscope while dynamic light scattering (DLS) measurements 
were performed using a Malvern Zetasizer 3000HSA (Malvern, Worcs., UK). Dissolved 
oxygen measurements were recorded using a Thermo Scientific™ DO Probe Orion™ 
083005MD (Fisher Scientific, Ottawa, ON, Canada) while nanoparticle solutions were mixed 
using a Silverson homogenizer (Silverson Machines Ltd, Chesham, U.K.). Fluorescence 
measurements were undertaken using a Cary Eclipse spectrophotometer while 96 well 
plates were analysed using a Fluostar Omega plate reader. Tumour pO2 measurements 
were performed using an Oxylite oxygen electrode sensor (Oxford Optronics, Oxford, UK). 
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NMR spectra were obtained on Varian 500 MHz instrument at 25.0 ± 1 oC and processed 
using Bruker software. Mass spectra were obtained using a Finnegan LCQ-MS instrument. 
Error in measurements was expressed as % standard error of the mean while statistical 
analysis was undertaken using 2-tailed Students t-test.  
 
2.2 Preparation of uncoated CaO2 NPs: CaO2 nanoparticles were prepared following the 
method described by Khodaveisi et al.[12] Ammonia solution (15.0 mL, 1M) and PEG 200 
(120.0 mL, 0.6744 mol) was added to a stirred solution of calcium chloride (3.0 g, 0.027mol) 
in distilled water (30mL). A solution of 35% H2O2 (15mL, 0.17mol) was then added to the 
mixture at a rate of 3 drops per minute and the colourless solution stirred for a further 2 h at 
room temperature. A NaOH solution (0.1 M) was then added until a pH value of 11.5 was 
achieved when the solution changed to a white coloured suspension. The precipitate was 
separated by centrifugation (8000g, 5 min) and the resulting pellet washed three times with 
NaOH (25 mL, 0.1 M). The precipitate was then washed with distilled water until the filtrate 
pH reached 8.4 and the resulting solid dried in vacuo  at 80oC for 2 h. The resulting particles 
were suspended in ethanol and sonicated for 5 minutes. The suspension was passed 
through a Millex Filter Unit (0.45μm) to isolate larger particles and the filtrate concentrated to 
dryness providing the uncoated CaO2 nanoparticles as a white powder. The size of the 
nanoparticles was determined by SEM and DLS.  
2.3: Determination of CaO2 content in the uncoated CaO2 NPs: The active CaO2 content 
of the NPs was determined by reaction with luminol in PBS. A chemiluminescence / 
concentration calibration curve for the reaction of H2O2 with luminol was performed 
according to the procedure adopted by Komagoe et al.[13] CaO2 NPs suspended in ethanol 
(50μL, 35.6μM) were added to a luminol solution (50μL, 10mg/mL in PBS) and the 
luminescence intensity determined using a plate reader. The CaO2 content was determined 
by indirectly measuring the number of moles of H2O2 produced (by reference to a calibration 
graph) from the fixed mass of CaO2 powder and assuming all the available CaO2 was 
converted to H2O2.  
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2.4: Determination of singlet oxygen generation: The ability of the CaO2 NPs to enhance 
PDT mediated singlet oxygen generation was determined using the singlet oxygen probe 
SOSG. CaO2 NPs (2mg) in de-oxygenated ethanol (1 mL) were added to a de-oxygenated 
PBS solution containing SOSG and RB resulting in final concentrations of 2.5 µM (SOSG), 
5.0 µM (RB) and 35.6 µM (CaO2 NPs). The solutions were then exposed to white light for 5 
min (Fenix LD01 LED,50 mW output,113.0 J/cm2) Control experiments were also undertaken 
and included (i) CaO2 NP + light and (ii) RB + light.  The intensity of SOSG fluorescence at 
525 nm upon excitation at 505 nm was recorded at the beginning and at the end of each 
experiment. 
2.5 In vitro PDT experiments: BxPc3 cells were seeded in a 96 well plate at a density of 5 
x 104 cells per well and incubated in a hypoxic chamber at 37 °C (O2/CO2/N2, 0.1: 5: 94.9, 
v/v/v) for 3 h. The cells were then treated with either (i) RB or (ii) RB with CaO2 NPs to reach 
a final concentration per well of 1μM (RB) and 25μM (CaO2) respectively. The CaO2 NPs 
were initially prepared in EtOH that was diluted 1:1 v/v with PBS (100 µL total volume) 
immediately before addition to wells containing 100 µL media leading to a total EtOH 
concentration of 25% v/v .Control wells containing untreated cells or cells treated with 
vehicle alone (i.e. EtOH / PBS 1:1 v/v 100 µL) were undertaken for comparative purposes. 
The cells were allowed to incubate with the drug / NPs / vehicle for 5 minutes, the medium 
was then removed and replaced with fresh media. The cells were then exposed to white light 
treatment for 30 sec (Fenix LD01 LED,50 mW output,11.3 J/cm2). Following light treatment 
cells were incubated for a further 3 h in the hypoxic chamber and then for a further  24 hours 
under normoxic conditions in a humidified 5% CO2 atmosphere at 37°C. Cell viability was 
then determined using a MTT assay.  
2.6 Preparation of polymer 1: 2-(dimethylamino)ethyl methacrylate (157.2 mg, 1mmol), 
methyl methacrylate (100.1mg, 2mmol) and ethyl acrylate (100.1mg, 1mmol) and a catalytic 
amount of the free radical initiator (ABCN) were dissolved in anhydrous THF (5mL) and 
placed in a Carious reaction vessel. The contents were then subjected to three freeze-pump-
thaw cycles, sealed under vacuum and placed in a Carious oven at 80°C for 72 h. The 
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contents were removed and hexane (20mL) added to the facilitate precipitation followed by 
centrifugation for 5 min at 3500g. The supernatant was removed, the pellet containing 1 re-
dissolved in anhydrous THF, precipitated again using hexane and centrifuged at 3743 x g. 
This purification procedure was repeated twice further before the pellet was dried in vacuo at 
80 oC and characterised by 1H NMR spectroscopy.  
2.7 Coating of CaO2 NPs with polymer 1 to form 1-CaO2 NPs:  CaO2 NPs were coated 
with 1 using a modified single emulsion method.[14] CaO2 NPs (10mg) were dispersed in 
hexane (10mL) and sonicated for 5 min. The NP suspension was then added dropwise at a 
rate of 2mL / min to a solution of 1 (100mg, 0.36µmol) in ethanol (40mL) using a Silverson 
homogeniser at 8000g for 5 min to ensure efficient mixing. After a further mixing period of 6 
h, excess solvent was allowed to slowly evaporate and the 1-CaO2 NPs reconstituted in 
sterile water. Particle size was then determined using SEM and DLS.  
2.8 Dissolved oxygen experiments: For the dissolved oxygen experiments involving the 
uncoated CaO2 NPs, an ethanol solution containing the NPs (10.0 mg, 24 mmol) was added 
to 10mL of de-oxygenated PBS solvent. The dissolved oxygen was then measured and 
recorded every minute using a dissolved oxygen meter. For dissolved oxygen experiments 
involving the 1-CaO2 NPs, separate solutions of de-oxygenated water were pH adjusted to 
pH 7.4 or 6.2. The 1-CaO2 NPs (2mg) were then added to each solution and the dissolved 
oxygen measured using a dissolved oxygen meter 3 min following addition. Results were 
compared against identical solutions in the absence of 1-CaO2 NPs. Both sets of 
experiments were repeated in triplicate.   
2.9 Solubility of 1-CaO2 NPs with change in pH: The pH of an aqueous suspension 
containing 1-CaO2 NPs (2 mg in 10 mL) was lowered from pH 7.4 to pH 6.2 in approximate 
0.1 pH increments following the addition of very small aliquots of 0.1 M HCl.  Photographs of 
the resulting suspensions / solutions were taken at pH 7.4, 6.9 and 6.2. 
2.9: Determination of tumour pO2:  All animals employed in this study were treated 
humanely and in accordance with licenced procedures under the UK Animals (Scientific 
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Procedures) Act 1986.  The ability of the 1-CaO2 NPs to influence tumour hypoxia was 
examined in a mouse xenograft tumour model of  human pancreatic cancer. MIA PaCa-2 
cells were maintained in RPMI-1640 medium supplemented with 10% foetal calf serum. 
Cells were cultured at 37 °C under 5% CO2 in air. The cells (5 × 10
6) were re-suspended in 
100 μL of Matrigel® (BD Biosciences, Erembodegem, Belgium) and implanted 
subcutaneously into the rear dorsum of male SCID mice. Tumour formation occurred 
approximately 5 weeks after implantation and tumour measurements were taken every other 
day using callipers. Once the tumours had reached an average volume of 254 ± 17 mm3 
calculated from the geometric mean diameter using the equation tumour volume = 
(W*H*L/2), animals were randomly distributed into two groups (n=3): (i) 1-CaO2 NPs and (ii) 
vehicle only. Following induction of anaesthesia via intraperitoneal injection of 
Hyponym/Hypnovel (150µl, i.p) of a mixture of 2:1:1; PBS: Hypnorm (0.315 mg/ml fentanyl 
citrate and fluanisone 10mg/ml, VetaPharma Ltd, U.K.): Hypnovel (10mg/ml midazolom, 
Roche, UK), the oxygen partial pressure (pO2) of tumours was recorded using an Oxylite 
oxygen electrode sensor. A fibre optic probe was inserted into a 21-gauge needle before 
insertion into the centre of the tumour tissue. The needle was withdrawn and the probe 
readings allowed to stabilise for 5 minutes. The pO2 in the tumours was recorded every 
second for 20 min.  100 µL aliquots of 1-CaO2 NPs in a PBS vehicle (2 mg/mL) or PBS alone 
were administered to the respective groups by tail-vein injection with pO2 recorded every 
second for a further 40 minutes. This time period was chosen to avoid the need for re-
administering anaesthesia.  
 
2.10 Effect of 1-CaO2 NPs on PDT efficacy in vivo: Mia-PaCa 2 xenograft tumours were 
established as described above. Once the tumours had reacted an average volume of 254 ± 
17 mm3 the mice were randomly separated into 4 groups (n=5). Group 1 involved untreated 
animals, group 2 the PDT only group, Group 3 the 1-CaO2 NPs only group and group 4 the 
PDT + 1-CaO2 NPs group. For group 2 mice received an intratumoural injection (100 µL) of 
Rose Bengal (0.1 mg/mL) in a PBS solvent and the tumour was then exposed to a LED-
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based white light source for 3 x 3 min treatments (Fenix LD01 LED,50 mW output,205 J/cm2) 
with a 1 minute interval between each treatment.  Group 3 received a tail vein injection (100 
µL) of 1-CaO2 NPs in a PBS vehicle (2 mg/mL) while group 4 also received a tail vein 
injection (100 µL) of 1-CaO2 NPs in a PBS vehicle (2 mg/mL) in addition to an intratumoural 
injection (100 µL) of Rose Bengal (0.1 mg/mL) and light exposure administered 20 min after 
NP injection using the same conditions as described for group 2. The tumour volume was 
measured daily over the course of 6 days using callipers. 
 
3.0  Results and Discussion: CaO2 NPs were prepared following a hydrolysis-precipitation 
procedure similar to that developed by J. Khodaveiside et al. that utilised CaCl2 as a calcium 
precursor and polyethylene glycol 200 (PEG200) as a surface modifier. The resulting 
particles were analysed by SEM and found to be spherical in shape with an average 
diameter of 116.0 ± 7.6 nm (Figure 1a). However, closer inspection of the particle 
morphology revealed the appearance of several smaller particles coalesced together to form 
the larger sized NPs. This was confirmed when an ethanol solution containing the NPs was 
analysed using DLS where the particle diameter was found to be much smaller at 21.0 nm ± 
11 nm. (Figure 1b). The amount of active CaO2 contained within the NP powder was 
determined by measuring the luminescence generated when a fixed amount of the NP 
powder was dissolved in an aqueous luminol solution. The hydrogen peroxide generated 
from the reaction of CaO2 with the aqueous medium (Equation 1) subsequently reacts 
quantitatively with luminol to produce a chemiluminescence signal that is proportional to the 
amount of hydrogen peroxide present.[15]  
 
2CaO2 + 4H2O → 2Ca(OH)2+2H2O2→ 2Ca(OH)2+ 2H2O+O2  Equation 1 
 
Using this approach, the amount of active CaO2 present in the NP powder was determined 
as 44.9 ± 2.3 % with the remaining mass due to excipients such as PEG.  
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Figure 1 (a) Representative SEM image and (b) DLS plot of CaO2 NPs.  
To determine the ability of the uncoated CaO2 NPs to generate molecular oxygen 
upon contact with water and improve oxygen levels in the immediate environment, a 
simulated hypoxic environment was generated by deoxygenating a solution of PBS (pH = 
7.4 ±0.1). A fixed amount of the CaO2 NPs was added to the solution and the amount of 
dissolved oxygen present in the solution determined as a function of time. The results are 
shown in Figure 2 and reveal a rapid increase in dissolved oxygen level (37.25%) 10 
minutes after NP addition with no further increase observed over the next 10 min suggesting 
all the CaO2 NPs were used. In contrast, a degassed PBS solution that was exposed to the 
open atmosphere increased by only 4.10 % over the same time period. These results 
demonstrate that the CaO2 NPs rapidly decompose when they come into contact with 
(b) 
(a) 
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aqueous medium generating a significant enhancement in the oxygen levels their immediate 
environment.  
 
Figure 2  Plot of % increase in dissolved oxygen against time for a solutions of de-
oxygenated PBS with (squares) and without (diamonds) addition of CaO2 NPs.  
 
It is well established that providing oxygen to an excited sensitiser during PDT can 
enhance the amount of ROS generated, particularly under hypoxic conditions.[16]  To 
identify if the improved dissolved oxygen levels generated by the CaO2 NPs would also 
translate to an increase in singlet oxygen quantum yield, the singlet oxygen probe sensor 
green (SOSG) was utilised. SOSG is inherently non-fluorescent but reacts with singlet 
oxygen to generate a fluorescent product with the fluorescence intensity being proportional 
to the amount of singlet oxygen generated. A de-oxygenated PBS solution (2:98; EtOH:H2O) 
containing SOSG (2.5 µM) and the sensitiser Rose Bengal (5 µM) was prepared and an 
ethanol solution containing CaO2 NPs (35.6 µM) added. Immediately, the solution was then 
irradiated with white light for 5 min at which point the fluorescence intensity at 530 nm was 
measured. Control experiments in the absence of the CaO2 NPs (i.e. RB, SOSG and light) 
and CaO2 NPs only (i.e. CaO2 NPs, SOSG, and light) were also conducted for comparative 
purposes. The results are shown in Figure 3 and reveal a significant increase (324.8%, 
p<0.001) in the amount of SOSG fluorescence observed for the solution containing CaO2 
NPs, RB and treated with light compared to the control experiments, indicating the ability of 
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the NPs to provide oxygen during the photodynamic event and enhance ROS generation in 
this simulated hypoxic environment. 
 
Figure 3   Plot of % increase in SOSG fluorescence at 510 nm for solutions containing (i) 
degassed PBS (ii) deoxygenated PBS and CaO2 NPs (iii) deoxygenated PBS and Rose 
Bengal (RB) and (iv) deoxygenated PBS, Rose Bengal and CaO2 NPs. Groups (ii)-(iv) also 
received light treatment. 
 
Having determined the ability of the CaO2 NPs to improve the light induced ROS 
generation of Rose Bengal in a simulated hypoxic environment, the next step was to 
determine if this improved ROS generation would also result in increased Rose Bengal 
mediated PDT induced toxicity using human BxPC-3 pancreatic cancer cells as a target. The 
cells were cultured in an anaerobic cabinet (O2/CO2/N2, 0.1: 5: 94.9 v/v/v) for 3h to generate 
a hypoxic environment and then treated with RB (1µM) and incubated for a further 3h under 
anaerobic conditions. This concentration of RB was identified from previous experiments to 
have a sub-lethal PDT effect in BxPC-3 cells cultured under hypoxic conditions and would 
therefore identify any beneficial effect provided by the NPs.[17] The cells were then 
incubated with an ethanol: PBS (50:50) suspension of the NPs (100 µL, 50 µM) for 5 min 
before being subjected to light treatment for 30 sec. The NP suspension was then removed, 
the cells washed with fresh PBS and incubated in fresh medium under normoxic conditions 
for a further 21 h before cell viability was determined using a MTT assay. The use of a 25% 
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v/v ethanolic NP suspension in these experiments was not ideal but care was taken to 
ensure that contact time with the cells was kept to a minimum. We also conducted vehicle 
only, RB only, light only and NP only controls for comparative purposes. The results are 
shown in Figure 4 and reveal a significant (p<0.01) reduction in viability for those cells 
treated with PDT in the presence of CaO2 NPs (57.9%) compared to PDT treatment alone 
(25.6%). In addition, there was no observable toxicity exhibited by the nanoparticles 
themselves at the concentration used in this experiment. These results suggest a synergistic 
effect between PDT and the CaO2 NPs in this cell line under these experimental conditions 
and that treatment of hypoxic BxPC3 with CaO2 NPs prior to PDT treatment can enhance 
oxygen levels improving the PDT mediated efficacy.  
 
Figure 4   Plot of cell viability for BxPC-3 cells, cultured under hypoxic conditions with (i) no 
treatment (CTRL dark bar)  or after treatment with (ii) light only (CTRL light bar) (iii) RB only 
in an EtOH vehicle (RB+EtOH black bar) (iv) RB in an EtOH vehicle + light (RB+EtOH light 
bar) (v) RB + CaO2 NP in an EtOH vehicle (RB+NP dark bar) (vi) RB + CaO2 NP+ light in an 
EtOH vehicle (RB+NP dark bar). 
 
If  CaO2 NPs are to be used in vivo it is imperative they remain stable in circulation 
until taken up by tumour tissue so that inadvertent systemic activation is avoided. In theory, it 
should be possible to coat the NPs with a polymer that has low aqueous solubility at 
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physiological pH (i.e. 7.4) but possesses increased solubility in environments where the pH 
is mildly acidic, as is the case in tumour extracellular fluid (pH = ~ 6.2). We prepared 
terpolymer 1, similar in structure to Eudragit E, by the free radical co-polymerisation of 2-
(dimethylamino)ethyl methacrylate, methylmethacyrlate and ethylmethacrylate in a 2:1:1 
ratio. Eudragit E has been shown to suppress drug release at pH 7.4 when used as a tablet 
coating but rapidly dissolves in acidic medium to release the active drug.[18] Like Eudragit E, 
1 contains a tertiary amine side chain making it possess low aqueous solubility as the free 
base but become soluble once ionised.[19] The successful preparation of 1 was confirmed 
by 1H NMR spectroscopy with the stacked spectra of each monomer and 1 shown in Fig 5. 
The olefinic protons present in the spectra of the monomers between 5.5 and 6.5 ppm were 
not present in 1 indicating they had been successfully polymerised to form the backbone of 
1. In addition, the peaks were much broader in the spectrum of 1 than in the monomers 
which is characteristic of protons in or near the backbone of polymers due to an ineffective 
averaging of their chemical shift anisotropies.[20] 
 
Figure 5  Stacked 1HNMR spectra of (i) methyl methacrylate (ii) ethyl acrylate (iii) 2-
(dimethylamino)ethyl methacrylate and (iv) pH responsive polymer 1.  
15 
 
 
1 was then used to coat the CaO2 NPs using a modified oil-in-water emulsion 
technique. A SEM image of the resulting 1-CaO2 NPs is shown in figure 6a and again 
reveals spherical particles with an average diameter of 248 ± 17 nm which was similar to the 
hydrodynamic diameter (278 ± 71 nm) determined by DLS.  
 
 
 
 
Figure 6 (a) SEM image and (ii) DLS plot of 1- CaO2 NPs. 
 
The ability of the 1-CaO2 NPs to generate oxygen as a function of solution pH was 
determined by monitoring the increase in dissolved oxygen. Degassed aqueous solutions 
containing 1-CaO2 NPs (1 mg/mL) were pH adjusted to either pH 7.4 or pH 6.2 and the 
change in dissolved oxygen measured at each pH 5 minutes later. The results are shown in 
figure 7 and reveal a 45% increase in dissolved oxygen at pH 6.2 compared to only 7% 
increase at pH 7.4. This increase in dissolved oxygen results from dissolution of the polymer 
(a) 
(b) 
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coat at lower pH that exposes the CaO2 core to the aqueous environment. Indeed, when an 
aqueous suspension containing 1-CaO2 NPs was pH adjusted from pH 7.4 to pH 6.2, the 
visual appearance changed from a milky suspension to a more transparent colloidal 
suspension. These results suggest that the 1-CaO2 NPs should remain stable in the 
systemic circulation at pH = 7.4 but become activated to release O2 when in the more acidic 
tumour microenvironment.   
 
   
 
 
Figure 7  (a) Plot of % dissolved oxygen for solutions of de-oxygenated water at pH 6.2 and 
pH 7.4 in the absence and presence of 1-CaO2 NPs. (b) Photographs showing an aqueous 
suspension of the polymer coated NPs at pH 7.44, 6.88 and 6.19.  
(a) 
(b) 
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To determine the ability of the 1-CaO2 NPs to enhance tumour oxygenation in an in 
vivo model, ectopic human xenograft MIA PaCa-2 tumours were established in SCID mice. 
The MIA-PaCa-2 model is known to form hypoxic tumours and has previously been used in 
therapeutic efficacy experiments involving hypoxia activated prodrugs.[21] Unlike the BxPC-
3 cell line, MIA PaCa-2 cells also express the KRAS mutation making it a more 
representative model of the disease in vivo. Once the tumours reached an average volume 
of 254 ± 17 mm3, the mice were separated into two groups (n=3). The treatment group 
received a tail vein injection of the 1-CaO2 NP suspension in a PBS buffer vehicle (pH 7.4 ± 
0.1), with the control group receiving the same volume of vehicle only. Tumour pO2 readings 
were recorded using an Oxylite oxygen electrode sensor for 20 min before and 40 min after 
injection.  
 
 
 
(a) 
(b) 
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Figure 8  (a) Plot of average tumour pO2 in mice bearing ectopic MIA PaCa-2 pancreatic 
tumours recorded for 20 min before and 40 min following an IV injection of 1 CaO2 NPs in a 
PBS (pH 7.4 ± 0.1) vehicle (red line) or vehicle only (blue dashed line). Arrow indicates when 
the injection occurred. (b) Plot showing the mean tumour pO2 for various time intervals 
before and following IV administration of polymer coated CaO2 NPs or vehicle only, obtained 
from integration of the plot shown in (a)., *p≤ 0.05. 
 
The results are shown in Figure 8 and reveal no significant change in the pO2 
reading in the 20 min period before injection for either group with a mean pO2 reading of ~ 
2.0 mmHg. However, approximately 10 min after injection, tumour pO2 levels in the 1-CaO2 
NP group increased dramatically reaching a peak of 16 mmHg before levelling off at ~6 
mmHg 30 min after injection. In contrast, mice treated with vehicle alone showed no 
noticeable change in tumour pO2 over the time course of the experiment.  
To put the above results in context, previous studies have indicated that the 
response to radiotherapy treatment is highly dependent upon tumour oxygenation with an 
increase from 2.5 mmHg to 6 mmHg significantly affecting loco-regional tumour control in 
advanced squamous cell head and neck carcinoma.[22] While similar data are not available 
for PDT, the technique is known to be negatively impacted by hypoxia and the increase in 
tumour pO2 levels provided by the 1-CaO2 NPs would be expected to have a beneficial effect 
on PDT mediated efficacy in vivo.[23-26] To confirm that this was the case, we treated the 
same MIA-PaCa-2 tumour model, described in the pO2 study above, with PDT using a Rose 
Bengal sensitiser in the presence and absence of the 1-CaO2 NPs. Untreated animals and 
those treated with 1-CaO2 NPs alone were used as controls. The NPs were again delivered 
by IV injection while Rose Bengal was administered by intratumoral injection, to ensure a 
consistent dose was administered to all of the tumours. Twenty minutes following IV 
administration of the 1-CaO2 NPs, tumours were exposed to light treatment for 3 min. 
Tumour volume was monitored for 5 days following treatment and the results are shown in 
Figure 9a. The results demonstrate that there was no significant difference in tumour volume 
for mice treated with PDT alone or with 1-CaO2 NPs alone 5 days after treatment, relative to 
19 
 
the untreated control animals. In contrast, a significant reduction (p ≤ 0.001) of 70.5 % was 
observed for animals treated with the 1-CaO2 NPs and PDT over the same time period. In 
addition, there was no significant change in body weight in animals treated with the 1-CaO2 
NPs alone or in combination with PDT suggesting the treatment was well tolerated (Figure 
9b). These results highlight the benefit of 1-CaO2 NPs in improving the PDT mediated 
treatment of hypoxic tumours such as pancreatic adenocarcinoma and may provide benefit 
in other treatments that are also compromised by hypoxia, most notably radiotherapy.  
 
 
(b) 
 
 
*** 
(a) 
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Figure 9. (a) Plot of % change in tumour volume against time for SCID mice bearing human 
xenograft MIA PaCa 2 pancreatic tumours treated with (i) no treatment (squares) (ii) PDT 
only (circles) (iii)  1-CaO2 NPs only (diamonds) and (iv) 1-CaO2 NPs and PDT (triangles). (b) 
Plot of average body weight for each group of mice over the time course of the experiment. 
***p ≤ 0.01. 
In summary, we have developed a CaO2 containing nanoparticle formulation 
comprising a pH-responsive coating that enables the generation of molecular oxygen in 
response to changes in environmental pH. Specifically, the polymer coat maintains its 
integrity when in aqueous solution at pH 7.4, but rapidly dissolves when the pH is lowered to 
pH 6.2, exposing the  CaO2 particles to water resulting in oxygen  generation. The ability of 
the coated particles to elevate tumour oxygen levels was also demonstrated in mice bearing 
human xenograft pancreatic tumours where significant elevations in tumour pO2 were 
observed 10 mins following IV administration. This increase in tumour pO2 was also shown 
to have a dramatic effect on the efficacy of PDT treatment with significant reductions in 
tumour growth observed in animals that received the coated particles prior to PDT treatment. 
The utility of this approach is not restricted to PDT but will surely also provide benefit in other 
treatments that are also negatively impacted by hypoxia.  
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Figures and Diagrams 
 
 
 
 
Scheme 1 Schematic illustration of how the polymer coat (green) protects the nanoparticle 
core (blue) from its aqueous environment at normal pH but at lower pH, the polymer coat 
dissolves, allowing access to the core by water with the resulting generation of oxygen.  
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Figure 1 (a) Representative SEM image and (b) DLS plot of CaO2 NPs.  
 
 
 
 
 
 
 
 
 
 
(b) 
(a) 
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Figure 2  Plot of % increase in dissolved oxygen against time for a solutions of de-
oxygenated PBS with (squares) and without (diamonds) addition of CaO2 NPs.  
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Figure 3   Plot of % increase in SOSG fluorescence at 510 nm for solutions containing (i) 
degassed PBS (ii) deoxygenated PBS and CaO2 NPs (iii) deoxygenated PBS and Rose 
Bengal (RB) and (iv) deoxygenated PBS, Rose Bengal and CaO2 NPs. Groups (ii)-(iv) also 
received light treatment. 
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Figure 4   Plot of cell viability for BxPC-3 cells, cultured under hypoxic conditions with (i) no 
treatment (CTRL dark bar)  or after treatment with (ii) light only (CTRL light bar) (iii) RB only 
in an EtOH vehicle (RB+EtOH black bar) (iv) RB in an EtOH vehicle + light (RB+EtOH light 
bar) (v) RB + CaO2 NP in an EtOH vehicle (RB+NP dark bar) (vi) RB + CaO2 NP+ light in an 
EtOH vehicle (RB+NP dark bar). 
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Figure 5  Stacked 1HNMR spectra of (i) methyl methacrylate (ii) ethyl acrylate (iii) 2-
(dimethylamino)ethyl methacrylate and (iv) pH responsive polymer 1.  
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Figure 6 (a) SEM image and (ii) DLS plot of 1- CaO2 NPs. 
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Figure 7  (a) Plot of % dissolved oxygen for solutions of de-oxygenated water at pH 6.2 and 
pH 7.4 in the absence and presence of 1-CaO2 NPs. (b) Photographs showing an aqueous 
suspension of the polymer coated NPs at pH 7.44, 6.88 and 6.19.  
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Figure 8  (a) Plot of average tumour pO2 in mice bearing ectopic MIA PaCa-2 pancreatic 
tumours recorded for 20 min before and 40 min following an IV injection of 1 CaO2 NPs in a 
PBS (pH 7.4 ± 0.1) vehicle (red line) or vehicle only (blue dashed line). Arrow indicates when 
the injection occurred. (b) Plot showing the mean tumour pO2 for various time intervals 
before and following IV administration of polymer coated CaO2 NPs or vehicle only, obtained 
from integration of the plot shown in (a)., *p≤ 0.05. 
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Figure 9. (a) Plot of % change in tumour volume against time for SCID mice bearing human 
xenograft MIA PaCa 2 pancreatic tumours treated with (i) no treatment (squares) (ii) PDT 
only (circles) (iii)  1-CaO2 NPs only (diamonds) and (iv) 1-CaO2 NPs and PDT (triangles). (b) 
Plot of average body weight for each group of mice over the time course of the experiment. 
***p ≤ 0.01. 
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